The concept of modifying radiopharmaceuticals with an albumin-bindingentity to enhance their blood circulation time and, therewith, thetumor uptake has been exemplified witha variety of tumor-targeting agents, includingfolate radioconjugates,−,  prostate-specific membrane antigen(PSMA)-targeting radioligands,−, , , , ,  and somatostatin analogues. These preclinicalstudies indicate the necessity of identifying the optimal albuminbinder and spacer entity separately for each tumor-targeting agentthrough systematic investigations to achieve the desired distributionprofile. This evidence concerns the gene ALB and neoplasm.